J9340 HCPCS Level II code: Injection, thiotepa, 15 mg
CMS terminated J9340: its last date of service was Jun 30, 2025. It stays here for looking up older claims; newer services need a current code.
Official description
J9340Injection, thiotepa, 15 mg
Short description: Thiotepa injection
HCPCS · United States
Medicare details
The indicators CMS publishes with J9340 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Added
- Jan 1, 1984
- Terminated after
- Jun 30, 2025
Where J9340 sits
- 1J codesDrugs administered other than orally
- 2Terminated J9340Injection, thiotepa, 15 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code J9340 still valid?
No. CMS terminated J9340; its last date of service was Jun 30, 2025. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover J9340?
CMS lists J9340’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9340
All J codesJ9329Injection, tislelizumab-jsgr, 1mgJ9330Injection, temsirolimus, 1 mgJ9331Injection, sirolimus protein-bound particles, 1 mgJ9332Injection, efgartigimod alfa-fcab, 2mgJ9333Injection, rozanolixizumab-noli, 1 mgJ9334Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfcJ9341Injection, thiotepa (tepylute), 1 mgJ9342Injection, thiotepa, not otherwise specified, 1 mgJ9345Injection, retifanlimab-dlwr, 1 mgJ9347Injection, tremelimumab-actl, 1 mgJ9348Injection, naxitamab-gqgk, 1 mgJ9349Injection, tafasitamab-cxix, 2 mg